SavedAdd your journal

Journals / Medicine Science / 2015 / Cilt: 4 - Sayı: 1

Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma

Mazhar Müslüm TUNA
Bercem Aycicek DOGAN
Mehtap Navdar BAŞARAN
Ayşe ARDUÇ
DİLEK BERKER
Serdar GÜLER
Pages
1985–1992
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, beneficial metabolic changes were seen in patients with prolactinoma after treatment with cabergoline.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It has been suggested that hyperprolactinemia may be associated with obesity and dyslipidemia.
📊
Key Findings & Data:This study was a single-centre, prospective, case-control study, consisted of 53 patients with symptomatic prolactinoma (group 1) and 57 healty women (group 3).
💡
Conclusion & Impact:In conclusion, beneficial metabolic changes were seen in patients with prolactinoma after treatment with cabergoline.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

It has been suggested that hyperprolactinemia may be associated with obesity and dyslipidemia. However it is not fully understood that dyslipidemia is occurs independently or due to obesity. The study was aimed to investigate lipid abnormalities and androgen hormone levels before and after cabergolin (CAB) treatment in non- obese premenauposal patients with prolactinoma. This study was a single-centre, prospective, case-control study, consisted of 53 patients with symptomatic prolactinoma (group 1) and 57 healty women (group 3). All subjects underwent a physical examination, anthropometric measurement and a 12 hour fasting blood sample for fasting blood glucose and lipid levels. 49 patients with prolactinoma were reevaluated for metabolic parameters after one year of cabergolin treatment (group 2). The median age was 34 in group 1, and 33 in group 3 (p=0.522). The initially higher body mass index (BMI) in patients with prolactinoma became similar after one year of treatment those with control group (p=0.475). While LDL-C was significanly higher in group 1 than in controls, HDL was significanly lower in group 1. Also post- treatment values of LDL-C (p=0.440) and HDL-C (p=0.612) were not different from the control group. No correlation was found between baseline prolactin levels and FSH, LH, LDL-C, HDL-C (p=0.129, p=0.658, p=0.817, p=0.760 respectively). In conclusion, beneficial metabolic changes were seen in patients with prolactinoma after treatment with cabergoline. Thus considering the metabolic profile and an appropriate treatment goal is important in the clinical management of patients with prolactinoma.

🔖

Cite This Article

TUNA, M. M., DOGAN, B. A., BAŞARAN, M. N., ARDUÇ, A., BERKER, D., GÜLER, S. (2015). Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma. Medicine Science, Cilt: 4 - Sayı: 1, 1985–1992. https://ajindex.com/articles/277720

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8(1):3-6
  2. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology. 2010;72(3):377-82
  3. Kars M, Dekkers OM, Pereira AM, Romijn JA. Update in prolactinomas. Neth J Med. 2010;68(3):104-12
  4. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17(3):110-6
  5. Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147(1):77-84
  6. Ling C, Svensson L, Odén B, Weijdegård B, Edén B, Edén S, Billig H. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003;88(4):1804-8
  7. Hesmati HM, Turpin G, de Gennes JL. Chronic hyperprolactinaemia and plasma lipids in women. Klin Wochenschr. 1987;65(11):516-9
  8. Jiang XB, Li CL, He DS, Mao ZG, Liu DH, Fan X, Hu B, Zhu YH, Wang HJ. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary. 2014;17(3):232-9
  9. Berinder K, Stackenäs I, Akre O, Hirschberg AL, Hulting AL. Hyperprolactinemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol (Oxf). 2005;63(4):450-5
  10. Delgrange E, Donckier J, Maiter D. Hyperprolactinaemia as a reversible cause of weight gain in male patients? Clin Endocrinol (Oxf). 1999;50(2):271
  11. Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary. 2009;12(2):96-104
  12. Dos SSC, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity. 2011;19(4):800-5
  13. Kopelman PG. Physiopathology of prolactin secretion in obesity. Int J Obes Relat Metab Disord. 2000;24(2):104-8
  14. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006;64(4):366-70
  15. Naliato EC(1), Violante AH, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Souza RG, Costa PL, Colao A.